Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Olema Pharmaceuticals Inc (OLMA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Olema's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
10.20 -0.20    -1.92%
16:53:03 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 72,115
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 10.20 - 10.56
Type:  Equity
Market:  United States
Olema 10.20 -0.20 -1.92%

Olema Company Profile

 
Read the Olema Pharmaceuticals Inc company profile to learn more about the business and the management team. View Olema Pharmaceuticals Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

70

Equity Type

ORD

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Contact Information

Address 780 Brannan Street
San Francisco, 94103
United States
Phone 415-651-3316
Fax -
Web olema.com

Top Executives

Name Age Since Title
Gorjan Hrustanovic 35 2018 Independent Director
Frank P. McCormick 74 2014 Chairman of Scientific Advisory Board
Sandra J. Horning 75 2020 Independent Director
Sean W. Fanning - - Member of Scientific Advisory Board
Mark Sliwkowski - - Member of Scientific Advisory Board
Christopher C. Benz - - Member of Scientific Advisory Board
Cynthia Marie Butitta 70 2020 Independent Director
Yi Larson 43 2021 Independent Director
Pamela M. Klein 63 2020 Member of Scientific Advisory Board
Cyrus L. Harmon 53 2006 Director
Andrew S. Rappaport 65 2013 Independent Director
Sean P. Bohen 57 2020 President, CEO & Director
Graham Gordon Walmsley 37 2020 Independent Director
Ian T. Clark 64 2020 Independent Chairperson of the Board
Pamela Munster - - Member of Scientific Advisory Board
Jeffrey Hager 59 - Member of Scientific Advisory Board
Geoffrey Greene - - Member of Scientific Advisory Board
Scott Garland 55 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

OLMA Price Commentary

Write your thoughts about Olema Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email